Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8181213 | 0.84 | TSHR (0.48) | MPOALDH1A1CA2MEN1KMT2A | |
| SCHEMBL19373091 | 0.82 | GAA (0.47) | MPOCA2CYP2D6TSHRHIF1A | |
| SCHEMBL21799844 | 0.79 | CA2 (0.44) | MPOTPOALDH1A1CA2CYP1A2 | |
| SCHEMBL23374589 | 0.77 | CHRM2 (0.56) | ALDH1A1CA2MEN1KMT2AGAA | |
| SCHEMBL31558942 | 0.77 | CHRM2 (0.56) | ALDH1A1CA2MEN1KMT2AGAA | |
| SCHEMBL6350780 | 0.76 | LIPG (0.43) | MPOTPOALDH1A1CA2CYP1A2 | |
| SCHEMBL18756245 | 0.76 | TSHR (0.67) | MPOCA2CYP2D6TSHRHIF1A | |
| SCHEMBL15770227 | 0.76 | CHRM2 (0.56) | ALDH1A1CYP2C19MEN1KMT2ACYP2D6 | |
| SCHEMBL172639 | 0.76 | MPO (0.49) | MPOALDH1A1MEN1KMT2AGAA | |
| SCHEMBL22512903 | 0.75 | TSHR (0.47) | MPOTPOALDH1A1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | MPO 3055/4885TPO 577/4885ALDH1A1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.